Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the MarketThe Motley Fool • 04/06/23
The Government Move That Could Drive Obesity Drugs — And Lilly, Novo SharesInvestors Business Daily • 03/29/23
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh WinInvestors Business Daily • 03/24/23
Novo Nordisk to slash US prices of insulin pens and vials by up to 75% for people with diabetesProactive Investors • 03/14/23
Novo Nordisk to lower prices of some insulins, following similar move by LillyMarket Watch • 03/14/23
Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024PRNewsWire • 03/14/23
AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains SteamInvestors Business Daily • 03/04/23
Europe will lose out on medical innovation if draft EU reforms pass -Novo Nordisk CEOReuters • 03/02/23